{"title":"Personalized immunization against Mpox Clades I and Ib: Strategies to combat the emerging epidemic","authors":"Deepak Kumar , Rishabha Malviya , Shriyansh Srivastava , Sathvik Belagodu Sridhar , Sirajunisa Talath , Javedh Shareef , Bhupendra G. Prajapati","doi":"10.1016/j.imj.2025.100166","DOIUrl":null,"url":null,"abstract":"<div><div>Mpox, formerly known as monkeypox, is a zoonotic virus of the <em>Orthopoxvirus</em> genus, with recent outbreaks of Clade I and Ib in Central Africa presenting a considerable global health threat. This study reviews current Mpox immunization approaches, focusing on the MVA-BN, LC16-KMB, and OrthopoxVac vaccines. MVA-BN vaccination has been successful in lowering infection risks, particularly in high-risk individuals and is widely used in the USA. LC16-KMB is recommended by the World Health Organization for prevention in afflicted regions. OrthopoxVac, a newer vaccination authorized in Russia, provides wide protection. Adapting vaccination approaches based on epidemiology in particular areas is critical for minimizing Mpox outbreaks.</div></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"4 1","pages":"Article 100166"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772431X2500005X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mpox, formerly known as monkeypox, is a zoonotic virus of the Orthopoxvirus genus, with recent outbreaks of Clade I and Ib in Central Africa presenting a considerable global health threat. This study reviews current Mpox immunization approaches, focusing on the MVA-BN, LC16-KMB, and OrthopoxVac vaccines. MVA-BN vaccination has been successful in lowering infection risks, particularly in high-risk individuals and is widely used in the USA. LC16-KMB is recommended by the World Health Organization for prevention in afflicted regions. OrthopoxVac, a newer vaccination authorized in Russia, provides wide protection. Adapting vaccination approaches based on epidemiology in particular areas is critical for minimizing Mpox outbreaks.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
